Cancer is the second leading cause of death globally, and about 1 in 6 deaths is due to cancer. It is ĞƐƟmĂƚĞĚ that 7.6 million deaths due to cancer in the year 2005 by WHO (world health ŽƌŐĂnŝnjĂƟŽnÍ¿Í• this number expected to rise to 12 million deaths by the year 2030. Up to 2001, Malaysia did not have a EĂƟŽnĂů Cancer Registry (NCR) to ĞƐƟmĂƚĞ the real incidence of cancer among Malaysians. ǀĂůƵĂƟŽn of NCR reports indicates that the number of new cancer cases among residents in Peninsular Malaysia has decreased from 26,089 to 21,773. ŌĞƌ taking this report into account unregistered cases, the probability that a Malaysian will get cancer in his/her life ÆŸmÄž is 1 in 4. Since Lifestyle changes such as lack of regular exercise, ĐŽnƐƵmƉƟŽn of a high fat diet, and breast feeding habits are reported as some important risk factors among Malaysian breast cancer ƉĂƟĞnƚƐ͘ This report studies the global market size of Cancer Drugs in key regions like North America, Europe, Asia WĂĐŝĮĐ͕ Central & South America and Middle East & Africa, focuses on the ĐŽnƐƵmƉƟŽn of Cancer Drugs in these regions, this report categorizes the global Cancer Drugs market by players/brands, region, type and ĂƉƉůŝĐĂƟŽn and also studies the global market status, ĐŽmƉĞƟƟŽn landscape, growth rate, future trends, ŽƉƉŽƌƚƵnŝƟĞƐ and challenges, sales channels, distributors and Porter’s Five Forces Analysis.